Habitual coffee consumption and risk of dementia in older persons: modulation by CYP1A2 polymorphism.

Alzheimer’s disease CYP1A2 Caffeine Coffee Dementia

Journal

European journal of epidemiology
ISSN: 1573-7284
Titre abrégé: Eur J Epidemiol
Pays: Netherlands
ID NLM: 8508062

Informations de publication

Date de publication:
31 Oct 2023
Historique:
received: 28 06 2023
accepted: 11 10 2023
medline: 31 10 2023
pubmed: 31 10 2023
entrez: 31 10 2023
Statut: aheadofprint

Résumé

Higher coffee consumption has been associated with reduced dementia risk, yet with inconsistencies across studies. CYP1A2 polymorphisms, which affects caffeine metabolism, may modulate the association between coffee and the risk of dementia and Alzheimer's disease (AD). We included 5964 participants of the Three-City Study (mean age 74 years-old), free of dementia at baseline when they reported their daily coffee consumption, with available genome-wide genotyping and followed for dementia over a median of 9.0 (range 0.8-18.7) years. In Cox proportional-hazards models, the relationship between coffee consumption and dementia risk was modified by CYP1A2 polymorphism at rs762551 (p for interaction = 0.034). In multivariable-adjusted models, coffee intake was linearly associated with a decreased risk of dementia among carriers of the C allele only ("slower caffeine metabolizers"; HR for 1-cup increased [95% CI] 0.90 [0.83-0.97]), while in non-carriers ("faster caffeine metabolizers"), there was no significant association but a J-shaped trend toward a decrease in dementia risk up to 3 cups/day and increased risk beyond. Thus, compared to null intake, drinking ≥ 4 cups of coffee daily was associated with a reduced dementia risk in slower but not faster metabolizers (HR [95% CI] for ≥ 4 vs. 0 cup/day = 0.45 [0.25-0.80] and 1.32 [0.89-1.96], respectively). Results were similar when studying AD and another CYP1A2 candidate polymorphism (rs2472304), but no interaction was found with CYP1A2 rs2472297 or rs2470893. In this cohort, a linear association of coffee intake to lower dementia risk was apparent only among carriers of CYP1A2 polymorphisms predisposing to slower caffeine metabolism.

Identifiants

pubmed: 37906419
doi: 10.1007/s10654-023-01060-x
pii: 10.1007/s10654-023-01060-x
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Agence Nationale de la Recherche
ID : COGINUT ANR-06-PNRA-005

Informations de copyright

© 2023. Springer Nature B.V.

Références

Arendash GW, Mori T, Cao C, Mamcarz M, Runfeldt M, Dickson A, et al. Caffeine reverses cognitive impairment and decreases brain amyloid-β levels in aged Alzheimer’s disease mice. J Alzheimer’s Dis. 2009;17:661–80.
Wu L, Sun D, He Y. Coffee intake and the incident risk of cognitive disorders: a dose–response meta-analysis of nine prospective cohort studies. Clin Nutr. 2017;36:730–6.
pubmed: 27288328
Larsson SC, Orsini N. Coffee consumption and risk of dementia and Alzheimer’s disease: a dose-response meta-analysis of prospective studies. Nutrients. 2018;10: 1501.
pubmed: 30322179 pmcid: 6213481
Djordjevic N, Ghotbi R, Jankovic S, Aklillu E. Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163 C > A polymorphism. Eur J Clin Pharmacol. 2010;66:697–703.
pubmed: 20390257
Popat RA, Van Den Eeden SK, Tanner CM, Kamel F, Umbach DM, Marder K, et al. Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson’s disease. Eur J Neurol. 2011;18:756–65.
pubmed: 21281405 pmcid: 3556904
Kapellou A, King A, Graham CAM, Pilic L, Mavrommatis Y. Genetics of caffeine and brain-related outcomes—a systematic review of observational studies and randomized trials. Nutr Rev. 2023. https://doi.org/10.1093/nutrit/nuad029/7111264 .
pubmed: 37029915
Cornelis MC, Bennett DA, Weintraub S, Schneider JA, Morris MC. Caffeine consumption and dementia: are lewy bodies the link? Ann Neurol. 2022;91:834–46.
pubmed: 35288978 pmcid: 9310711
Cornelis MC, Kacprowski T, Menni C, Gustafsson S, Pivin E, Adamski J, et al. Genome-wide association study of caffeine metabolites provides new insights to caffeine metabolism and dietary caffeine-consumption behavior. Hum Mol Genet. 2016;25:5472–82.
pubmed: 27702941
Poole R, Kennedy OJ, Roderick P, Fallowfield JA, Hayes PC, Parkes J. Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes. BMJ. 2017;359.
pubmed: 29167102 pmcid: 5696634
Larsson SC, Woolf B, Gill D. Plasma caffeine levels and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomization study. Nutrients. 2022;14: 1697.
pubmed: 35565667 pmcid: 9102212
Nordestgaard AT, Nordestgaard BG, Frikke-Schmidt R, Juul Rasmussen I, Bojesen SE. Self-reported and genetically predicted coffee consumption and smoking in dementia: a Mendelian randomization study. Atherosclerosis. 2022;348:36–43.
pubmed: 35405480
Kim JW, Byun MS, Yi D, Lee JH, Jeon SY, Jung G, et al. Coffee intake and decreased amyloid pathology in human brain. Transl Psychiatry. 2019;9:1–10.
Pham K, Mulugeta A, Zhou A, O’Brien JT, Llewellyn DJ, Hyppönen E. High coffee consumption, brain volume and risk of dementia and stroke. Nutr Neurosci. 2022;25:2111–22.
pubmed: 34165394

Auteurs

Sophie Lefèvre-Arbogast (S)

University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219, 146 Rue Léo-Saignat, Bordeaux Cedex, 33076, France. Sophie.Lefevre-Arbogast@u-bordeaux.fr.

Catherine Helmer (C)

University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219, 146 Rue Léo-Saignat, Bordeaux Cedex, 33076, France.

Claudine Berr (C)

University of Montpellier, Institute for Neurosciences of Montpellier, Inserm, UMR 1298, Montpellier, 34091, France.

Stéphanie Debette (S)

University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219, 146 Rue Léo-Saignat, Bordeaux Cedex, 33076, France.

Cécilia Samieri (C)

University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219, 146 Rue Léo-Saignat, Bordeaux Cedex, 33076, France.

Classifications MeSH